NCT06526065 Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
| NCT ID | NCT06526065 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Goettingen |
| Condition | DLBCL - Diffuse Large B Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-06-20 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-06-20 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
Eligibility Criteria
Inclusion Criteria: 1. Histological diagnosis of DLBCL\&LBCL 2. Planned treatment with guideline-based first-line therapy 3. Patient's consent 4. All genders, Patient age ≥ 18 years 5. Ability to consent Exclusion Criteria: 1. Treatment with R-CHOP/-like regimens already started 2. Relationship of dependence/ direct employment with the investigator 3. Active HIV-infection 4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
Contact & Investigator
Lorenz Trümper
PRINCIPAL INVESTIGATOR
PI of the study
Frequently Asked Questions
Who can join the NCT06526065 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying DLBCL - Diffuse Large B Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06526065 currently recruiting?
Yes, NCT06526065 is actively recruiting participants. Contact the research team at anna-carina.hund@med.uni-goettingen.de for enrollment information.
Where is the NCT06526065 trial being conducted?
This trial is being conducted at Göttingen, Germany.
Who is sponsoring the NCT06526065 clinical trial?
NCT06526065 is sponsored by University Medical Center Goettingen. The principal investigator is Lorenz Trümper at PI of the study. The trial plans to enroll 500 participants.